Given the pivotal role of HMGN1 in peri-tumor infiltration of lymphocytes, combining HMGN1 targeting with immunotherapy might achieve better therapeutic outcomes for lung adenocarcinoma. This evidence concerns the gene HMGN1 and neoplasm.